Patient baseline and treatment characteristics
| Characteristics . | Total (N = 127), n (%) . | VEN cohort (n = 37), n (%) . | TPC cohort (n = 90), n (%) . | P value . |
|---|---|---|---|---|
| Sex | .695 | |||
| Male | 71 (56) | 22 (60) | 49 (54) | |
| Female | 56 (44) | 15 (40) | 41 (46) | |
| Age, median (range), y | 61 (22-79) | 62 (23-79) | 61 (22-79) | .661 |
| AML subtype | .271 | |||
| De novo | 93 (73) | 30 (81) | 63 (70) | |
| sAML | 34 (27) | 7 (19) | 27 (30) | |
| tAML | 13 (10) | 0 | 13 (16) | |
| Previous MDS, MPN, or MDS/MPN overlap | 21 (17) | 7 (19) | 14 (14) | |
| Status at start of salvage therapy | .422 | |||
| Refractory | 82 (65) | 26∗ (70) | 56 (62) | |
| Relapsed | 45 (35) | 11† (30) | 34 (38) | |
| Hematologic parameters at initial diagnosis | ||||
| WBC count, median (range), ×109/L (n = 125) | 17.1 (0.32-320.2) | 16.3 (0.32-226) | 18.4 (0.48-320.2) Missing n = 2 | .691 |
| Hemoglobin, median (range), g/dL (n = 124) | 9.3 (4.8-16.6) | 9.65 (5-13.4) Missing n = 1 | 9.1 (4.8-16.6) Missing n = 2 | .334 |
| PLT count, median (range), ×109/L (n = 124) | 48 (4-380) | 49 (4-253) Missing n = 1 | 48 (5-380) Missing n = 2 | .434 |
| Peripheral blood blasts, median (range), % (n = 112) | 34 (0-96) | 26 (0-95) Missing n = 5 | 42 (0-96) Missing n = 10 | .445 |
| Morphological BM blasts, median (range), % (n = 115) | 65 (8-98) | 60 (12-95) | 66 (8-98) Missing n = 12 | .512 |
| 2017 ELN risk stratification | .055 | |||
| Favorable | 32 (25) | 10 (27) | 22 (24) | .823 |
| Intermediate | 54 (43) | 10 (27) | 44 (49) | .030 |
| Adverse | 41 (32) | 17 (46) | 24 (27) | .039 |
| Cytogenetics | .552 | |||
| Aberrant | 43 (34) | 15 (40) | 28 (31) | |
| Complex aberrant | 13 (10) | 4 (11) | 9 (10) | |
| Normal | 71 (56) | 18 (49) | 53 (59) | |
| Genomic alteration | ||||
| NPM1 | 23 (18) | 8 (22) | 15 (17) | .613 |
| FLT3-ITD | 19 (15) | 6 (16) | 13 (14) | .789 |
| FLT3-TKD | 9 (7) | 1 (3) | 8 (9) | .282 |
| IDH1 | 14 (11) | 6 (16) | 8 (6) | .231 |
| IDH2 | 24 (19) | 9 (24) | 15 (17) | .327 |
| CEPBA (n = 122) | 20 (16) | 2 (5) | 18 (21) Missing n = 5 | .034 |
| TP53 (n = 94) | 12 (13) | 4 (11) Missing n = 2 | 8 (14) Missing n = 31 | 1.0 |
| ASXL1 (n = 94) | 13 (14) | 6 (17) Missing n = 2 | 7 (12) Missing n = 31 | .543 |
| RUNX1 (n = 94) | 17 (18) | 7 (20) Missing n = 2 | 10 (17) Missing n = 31 | .784 |
| TET2 (n = 94) | 27 (29) | 6 (17) Missing n = 2 | 21 (36) Missing n = 31 | .063 |
| Salvage setting | ||||
| Median no. of salvage therapy regimens (range) | 1 (1-6) | 1 (1-3) | 1 (1-6) | .180 |
| Patients proceeded to allo-HCT | 84 (66) | 27 (73) | 57 (63) | .409 |
| Conditioning regimens prior allo-HCT | .001 | |||
| Myeloablative | 47 (56) | 8 (30) | 39 (68) | |
| Nonmyeloablative and RIC | 37 (44) | 19 (70) | 18 (32) | |
| Previous therapy | ||||
| Prior allo-HCT for MDS | 2 (2) | 2 (5) | 0 (0) | |
| Prior intensive chemotherapy | 127 (100) | 37 (100) | 90 (100) |
| Characteristics . | Total (N = 127), n (%) . | VEN cohort (n = 37), n (%) . | TPC cohort (n = 90), n (%) . | P value . |
|---|---|---|---|---|
| Sex | .695 | |||
| Male | 71 (56) | 22 (60) | 49 (54) | |
| Female | 56 (44) | 15 (40) | 41 (46) | |
| Age, median (range), y | 61 (22-79) | 62 (23-79) | 61 (22-79) | .661 |
| AML subtype | .271 | |||
| De novo | 93 (73) | 30 (81) | 63 (70) | |
| sAML | 34 (27) | 7 (19) | 27 (30) | |
| tAML | 13 (10) | 0 | 13 (16) | |
| Previous MDS, MPN, or MDS/MPN overlap | 21 (17) | 7 (19) | 14 (14) | |
| Status at start of salvage therapy | .422 | |||
| Refractory | 82 (65) | 26∗ (70) | 56 (62) | |
| Relapsed | 45 (35) | 11† (30) | 34 (38) | |
| Hematologic parameters at initial diagnosis | ||||
| WBC count, median (range), ×109/L (n = 125) | 17.1 (0.32-320.2) | 16.3 (0.32-226) | 18.4 (0.48-320.2) Missing n = 2 | .691 |
| Hemoglobin, median (range), g/dL (n = 124) | 9.3 (4.8-16.6) | 9.65 (5-13.4) Missing n = 1 | 9.1 (4.8-16.6) Missing n = 2 | .334 |
| PLT count, median (range), ×109/L (n = 124) | 48 (4-380) | 49 (4-253) Missing n = 1 | 48 (5-380) Missing n = 2 | .434 |
| Peripheral blood blasts, median (range), % (n = 112) | 34 (0-96) | 26 (0-95) Missing n = 5 | 42 (0-96) Missing n = 10 | .445 |
| Morphological BM blasts, median (range), % (n = 115) | 65 (8-98) | 60 (12-95) | 66 (8-98) Missing n = 12 | .512 |
| 2017 ELN risk stratification | .055 | |||
| Favorable | 32 (25) | 10 (27) | 22 (24) | .823 |
| Intermediate | 54 (43) | 10 (27) | 44 (49) | .030 |
| Adverse | 41 (32) | 17 (46) | 24 (27) | .039 |
| Cytogenetics | .552 | |||
| Aberrant | 43 (34) | 15 (40) | 28 (31) | |
| Complex aberrant | 13 (10) | 4 (11) | 9 (10) | |
| Normal | 71 (56) | 18 (49) | 53 (59) | |
| Genomic alteration | ||||
| NPM1 | 23 (18) | 8 (22) | 15 (17) | .613 |
| FLT3-ITD | 19 (15) | 6 (16) | 13 (14) | .789 |
| FLT3-TKD | 9 (7) | 1 (3) | 8 (9) | .282 |
| IDH1 | 14 (11) | 6 (16) | 8 (6) | .231 |
| IDH2 | 24 (19) | 9 (24) | 15 (17) | .327 |
| CEPBA (n = 122) | 20 (16) | 2 (5) | 18 (21) Missing n = 5 | .034 |
| TP53 (n = 94) | 12 (13) | 4 (11) Missing n = 2 | 8 (14) Missing n = 31 | 1.0 |
| ASXL1 (n = 94) | 13 (14) | 6 (17) Missing n = 2 | 7 (12) Missing n = 31 | .543 |
| RUNX1 (n = 94) | 17 (18) | 7 (20) Missing n = 2 | 10 (17) Missing n = 31 | .784 |
| TET2 (n = 94) | 27 (29) | 6 (17) Missing n = 2 | 21 (36) Missing n = 31 | .063 |
| Salvage setting | ||||
| Median no. of salvage therapy regimens (range) | 1 (1-6) | 1 (1-3) | 1 (1-6) | .180 |
| Patients proceeded to allo-HCT | 84 (66) | 27 (73) | 57 (63) | .409 |
| Conditioning regimens prior allo-HCT | .001 | |||
| Myeloablative | 47 (56) | 8 (30) | 39 (68) | |
| Nonmyeloablative and RIC | 37 (44) | 19 (70) | 18 (32) | |
| Previous therapy | ||||
| Prior allo-HCT for MDS | 2 (2) | 2 (5) | 0 (0) | |
| Prior intensive chemotherapy | 127 (100) | 37 (100) | 90 (100) |
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; PLT, platelet; RIC, reduced-intensity conditioning; sAML, secondary AML; tAML, therapy-related AML; WBC, white blood cell.
P values < 0.05 are displayed in bold.
n = 26 (including 25 with refractory AML and 1 with AML in morphologic remission but with molecular disease persistence).
n = 11 (including 9 with morphologic relapse and 2 with molecular relapse).